Insights
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
A critique of the recent EEPRU paper
Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
12 November 2024
More collaborative initiatives are taking place among regulatory agencies, health technology assessment (HTA) bodies and between regulatory and HTA agencies at national and regional levels.
The Preventive Health Revolution: Insights from the 2024 Annual Lecture
15 October 2024
One of OHE’s charitable objectives is a commitment to educate and inform the public and policymakers about critical issues in the healthcare sector. OHE’s Annual Lecture…
Drug shortages are on the rise – but what is their impact?
16 September 2024
In this article, we discuss the global issue of drug shortages. We summarise our research where we developed a framework for quantifying the cost of a shortage, and through three case studies provide illustrative estimates of these costs.
Green Healthcare: Are We Asking the Right Questions?
11 September 2024
The climate-health crisis is a growing global concern, and identifying the right starting points is crucial.
Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool
9 September 2024
In our Around the World in HTAs insight series we shed light on HTA successes and challenges around the world. In this edition, Sarin KC, Manit Sittimart, Chittawan Poonsiri, Yi Wang, and Simon Brassel take us to Thailand.
R&D for new drugs to tackle AMR is a high-return investment for all EU member states
19 July 2024
Two recently-published papers predict high returns from a policy which incentivises the development of new antibiotics.
Around the World in HTAs: United States – Making HTA Great Again
11 June 2024
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Chris Sampson and Dan Ollendorf take us to the United States.
Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
10 June 2024
Tackling cancer is a major global priority. Early detection and diagnosis can help patients get timely access to treatment and dramatically improve cancer outcomes. This relies, in part, on the effective diagnostic tests.